Commonly displaying KRAS mutations, especially KRAS G12D and G12V which promote constitutive activation of the RAS-RAF-MEK-ERK signaling cascade are pancreatic, colorectal, and lung cancers. The gene discussed is KRAS; the disease is lung carcinoma.